We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Thallion and LFB Complete Patient Enrollment of Phase II SHIGATEC Trial

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Thallion and LFB Complete Patient Enrollment of Phase II SHIGATEC Trial"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

"The timely completion of patient recruitment and the two month patient follow up sets the stage for reporting top line SHIGATEC results early in the second quarter," said Dr. Allan Mandelzys, Thallion's Chief Executive Officer. "With the achievement of this significant milestone, we are now focused on moving forward with our anticipated Phase III clinical trial."

"We remain excited about the potential Shigamabs® represents in delivering an important therapy to the thousands of people who suffer from this terrible and potentially life-threatening infection each year" said Guillaume Bologna, Executive Vice-President for Development Programs of LFB Biotechnologies.